CL2017000469A1 - Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1 - Google Patents

Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1

Info

Publication number
CL2017000469A1
CL2017000469A1 CL2017000469A CL2017000469A CL2017000469A1 CL 2017000469 A1 CL2017000469 A1 CL 2017000469A1 CL 2017000469 A CL2017000469 A CL 2017000469A CL 2017000469 A CL2017000469 A CL 2017000469A CL 2017000469 A1 CL2017000469 A1 CL 2017000469A1
Authority
CL
Chile
Prior art keywords
mcl
protein
inhibit
compounds
tetrahydronaphthalene derivatives
Prior art date
Application number
CL2017000469A
Other languages
English (en)
Inventor
Brian S Lucas
Sean P Brown
Yunxiao Li
Nick A Paras
Joshua Taygerly
Marc Vimolratana
Xianghong Wang
Ming Yu
Manuel Zancanella
Liusheng Zhu
Buenrostro Ana Gonzalez
Zhihong Li
Mike Elias Lizarzaburu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201462043929P priority Critical
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2017000469A1 publication Critical patent/CL2017000469A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. chlothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/42Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/56Unsaturated compounds containing hydroxy or O-metal groups containing halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/58Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08Bridged systems

Abstract

<p>SE PROPORCIONAN EN LA PRESENTE INHIBIDORES DE LA PROTEÍNA DE LEUCEMIA DE CÉLULAS MIELOIDES 1 (MCL-1), MÉTODOS DE SU PREPARACIÓN, COMPOSICIONES FARMACÉUTICAS RELACIONADAS, Y MÉTODOS DE USO DE LOS MISMOS. POR EJEMPLO, SE PROPORCIONAN EN LA PRESENTE COMPUESTOS DE LA FÓRMULA I,</p> <p>*inlcuir figura de estructura de pagina 380 (doc total) que es hoja resumen.</p> <p>Y SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS Y COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN LOS COMPUESTOS. LOS COMPUESTOS Y COMPOSICIONES PROPORCIONADAS EN LA PRESENTE SE PUEDEN USAR, POR EJEMPLO, EN EL TRATAMIENTO DE ENFERMEDADES O AFECCIONES, TAL COMO CÁNCER.</p>
CL2017000469A 2014-08-29 2017-02-27 Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1 CL2017000469A1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US201462043929P true 2014-08-29 2014-08-29

Publications (1)

Publication Number Publication Date
CL2017000469A1 true CL2017000469A1 (es) 2017-11-03

Family

ID=54238507

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000469A CL2017000469A1 (es) 2014-08-29 2017-02-27 Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1

Country Status (39)

Country Link
US (6) US9562061B2 (es)
EP (2) EP3424931B1 (es)
JP (1) JP6502479B2 (es)
KR (1) KR20170043661A (es)
CN (1) CN107001387B (es)
AP (1) AP2017009827A0 (es)
AR (1) AR101729A1 (es)
AU (1) AU2015308735B2 (es)
BR (1) BR112017004209A2 (es)
CA (1) CA2959615A1 (es)
CL (1) CL2017000469A1 (es)
CO (1) CO2017002998A2 (es)
CR (1) CR20170116A (es)
CY (1) CY1121195T1 (es)
DK (1) DK3186259T3 (es)
EA (1) EA031223B1 (es)
ES (2) ES2777478T3 (es)
HR (1) HRP20190053T1 (es)
HU (1) HUE041806T2 (es)
IL (2) IL250843A (es)
JO (1) JO3474B1 (es)
LT (1) LT3186259T (es)
MA (1) MA40111B1 (es)
ME (1) ME03313B (es)
MX (1) MX2017002656A (es)
PE (1) PE20170892A1 (es)
PH (1) PH12017500367B1 (es)
PL (1) PL3186259T3 (es)
PT (1) PT3186259T (es)
RS (1) RS58276B1 (es)
SG (1) SG11201701525WA (es)
SI (1) SI3186259T1 (es)
TN (1) TN2017000067A1 (es)
TR (1) TR201901312T4 (es)
TW (1) TWI676628B (es)
UA (1) UA118233C2 (es)
UY (1) UY36285A (es)
WO (1) WO2016033486A1 (es)
ZA (1) ZA201701763B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3474B1 (ar) 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
WO2017147410A1 (en) * 2016-02-25 2017-08-31 Amgen Inc. Compounds that inhibit mcl-1 protein
AU2017300738A1 (en) 2016-07-22 2019-02-07 Les Laboratoires Servier Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
JP6453507B2 (ja) 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Mcl−1タンパク質を阻害する化合物
EP3668878A1 (en) 2017-08-18 2020-06-24 Amgen Inc. Compounds that inhibit mcl-1 protein
WO2019046150A1 (en) 2017-08-29 2019-03-07 Amgen Inc. MACROCYCLIC COMPOUNDS FOR INHIBITING MCL-1 PROTEIN
EP3762393A1 (en) 2018-03-05 2021-01-13 Amgen Inc. Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere mcl-1 protein antagonists
JP6899975B2 (ja) 2018-05-14 2021-07-07 ギリアード サイエンシーズ, インコーポレイテッド Mcl−1阻害剤
WO2020097577A1 (en) * 2018-11-09 2020-05-14 Prelude Therapeutics, Incorporated Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein
US20210340158A1 (en) * 2019-01-18 2021-11-04 Ascentage Pharma (Suzhou) Co., Ltd. Macrocyclic spiroethers as mcl-1 inhibitors
UY38700A (es) 2019-05-20 2020-12-31 Novartis Ag Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso
US20200392153A1 (en) 2019-05-23 2020-12-17 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
WO2020263830A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
WO2021005043A1 (en) 2019-07-09 2021-01-14 Janssen Pharmaceutica Nv Macrocyclic spirocycle derivatives as mcl-1 inhibitors
EP3771469A1 (en) * 2019-07-30 2021-02-03 Amgen, Inc Formulations and dosages for administering a compound that inhibits mcl1 protein
WO2021047616A1 (zh) * 2019-09-12 2021-03-18 苏州亚盛药业有限公司 氧氮杂环庚烷类螺环化合物、中间体及其制备方法
US20210115140A1 (en) 2019-10-18 2021-04-22 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
WO2021087064A1 (en) 2019-10-31 2021-05-06 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
US20210179570A1 (en) * 2019-11-26 2021-06-17 Gilead Sciences, Inc. Processes and intermediates for preparing mcl1 inhibitors
WO2021130638A1 (en) 2019-12-24 2021-07-01 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
US20210277129A1 (en) 2020-02-14 2021-09-09 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
WO2021211922A1 (en) * 2020-04-16 2021-10-21 Prelude Therapeutics, Incorporated Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein
WO2021222522A1 (en) 2020-05-01 2021-11-04 Gilead Sciences, Inc. Cd73 inhibiting 2,4-dioxopyrimidine compounds
WO2021225833A1 (en) 2020-05-06 2021-11-11 Amgen Inc. Synthesis of sulfonamide intermediates
WO2021225835A1 (en) 2020-05-06 2021-11-11 Amgen Inc. Synthesis of vinylic alcohol intermediates
WO2021225823A1 (en) 2020-05-06 2021-11-11 Amgen Inc. Synthesis of vinylic protected alcohol intermediates
WO2021226009A1 (en) 2020-05-06 2021-11-11 Amgen Inc. Synthesis of vinyl cyclobutyl intermediates
WO2021226168A1 (en) 2020-05-06 2021-11-11 Amgen Inc. Ring closing synthesis of macrocyclic mcl-1 inhibitor intermediates

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US6042820A (en) 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
US6472375B1 (en) 1998-04-16 2002-10-29 John Wayne Cancer Institute DNA vaccine and methods for its use
ES2400371T3 (es) * 2005-07-07 2013-04-09 Abbott Laboratories Promotores de la apoptosis
EP3243814B1 (en) 2007-04-16 2018-10-17 AbbVie Inc. 7-substituted indole as mcl-1 inhibitors
DK2185562T3 (en) * 2007-07-27 2016-02-22 Janssen Pharmaceutica Nv PYRROLOPYRIMIDINES SUITABLE FOR TREATING PROLIFERATIVE DISEASES
EP2470527A4 (en) * 2009-08-20 2013-02-27 Merck Sharp & Dohme BENZOTRIAZOLE D ETHER DERIVATIVES
EP2485721A4 (en) * 2009-10-08 2016-05-18 Sanford Burnham Med Res Inst APOGOSSYPOLONE DERIVATIVES AS ANTICANCER AGENTS
JP5937968B2 (ja) * 2010-01-29 2016-06-22 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド Mcl‐1を調節する小分子、並びに細胞死、細胞分裂、細胞分化を調節する方法、及び疾患を治療する方法。
US9486422B2 (en) 2011-10-06 2016-11-08 The Regents Of The University Of Michigan Small molecule inhibitors of Mcl-1 and the uses of thereof
WO2013149124A1 (en) * 2012-03-29 2013-10-03 The Regents Of The University Of Michigan Small molecule inhibitors of mcl-1 and uses thereof
JO3474B1 (ar) 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
WO2017147410A1 (en) 2016-02-25 2017-08-31 Amgen Inc. Compounds that inhibit mcl-1 protein

Also Published As

Publication number Publication date
US10494381B2 (en) 2019-12-03
PT3186259T (pt) 2019-02-06
CN107001387A (zh) 2017-08-01
US20170088560A1 (en) 2017-03-30
AU2015308735B2 (en) 2019-03-14
AR101729A1 (es) 2017-01-11
EA031223B1 (ru) 2018-12-28
ME03313B (me) 2019-10-20
HRP20190053T1 (hr) 2019-02-22
ES2777478T3 (es) 2020-08-05
TR201901312T4 (tr) 2019-02-21
MA40111A1 (fr) 2018-06-29
JP6502479B2 (ja) 2019-04-17
JP2017525730A (ja) 2017-09-07
DK3186259T3 (en) 2019-02-25
SI3186259T1 (sl) 2019-03-29
US20190016736A1 (en) 2019-01-17
NZ729768A (en) 2021-06-25
KR20170043661A (ko) 2017-04-21
HUE041806T2 (hu) 2019-05-28
EP3186259A1 (en) 2017-07-05
CO2017002998A2 (es) 2017-07-19
TN2017000067A1 (en) 2018-07-04
AP2017009827A0 (en) 2017-03-31
WO2016033486A1 (en) 2016-03-03
ZA201701763B (en) 2018-08-29
US20200062780A1 (en) 2020-02-27
IL257942D0 (en) 2018-05-31
ES2706309T3 (es) 2019-03-28
US9562061B2 (en) 2017-02-07
UA118233C2 (uk) 2018-12-10
MA40111B1 (fr) 2018-12-31
IL257942A (en) 2020-05-31
CR20170116A (es) 2017-04-28
EP3424931A3 (en) 2019-02-20
TW201625645A (zh) 2016-07-16
US20190023720A1 (en) 2019-01-24
EP3424931A2 (en) 2019-01-09
IL250843D0 (en) 2017-04-30
CN107001387B (zh) 2019-03-05
UY36285A (es) 2016-04-01
PL3186259T3 (pl) 2019-04-30
EA201790492A1 (ru) 2017-07-31
SG11201701525WA (en) 2017-03-30
BR112017004209A2 (pt) 2018-07-31
MX2017002656A (es) 2017-10-12
US10836779B2 (en) 2020-11-17
AU2015308735A1 (en) 2017-03-23
CA2959615A1 (en) 2016-03-03
PH12017500367B1 (en) 2017-07-10
JO3474B1 (ar) 2020-07-05
US20160068545A1 (en) 2016-03-10
US20210040120A1 (en) 2021-02-11
CY1121195T1 (el) 2020-05-29
EP3424931B1 (en) 2020-02-12
US10100063B2 (en) 2018-10-16
EP3186259B1 (en) 2018-12-19
PH12017500367A1 (en) 2017-07-10
LT3186259T (lt) 2019-02-25
TWI676628B (zh) 2019-11-11
IL250843A (en) 2018-03-29
RS58276B1 (sr) 2019-03-29
US11001598B2 (en) 2021-05-11
PE20170892A1 (es) 2017-07-12

Similar Documents

Publication Publication Date Title
CL2017000469A1 (es) Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1
CL2019002777A1 (es) Compuestos que inhiben la proteína mcl-1.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
CR20170563A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
GT201600123A (es) Inhibidores de syk
CL2019001077A1 (es) Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer.
UY35586A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
CR20190301A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
NI201500096A (es) Compuesto químicos
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
SV2018005663A (es) Compuestos de imidazo [4,5-c] quinolin-2-ona y su uso en el tratamiento del cancer
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
AR101414A1 (es) Derivados de pirrolidinona como inhibidores de metap-2
UY35419A (es) Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina
NI201600176A (es) Compuestos de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer.
CL2017000682A1 (es) Compuestos novedosos de imidazopiridazina y su uso.
NI201800071A (es) Compuestos de isoindol
PE20151607A1 (es) Formulaciones de compuestos organicos
ECSP18056196A (es) Derivados de indano
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer